To include your compound in the COVID-19 Resource Center, submit it here.

Benefit of PD-1/PD-L1 treatment lasts beyond discontinuation

New research from the Dana-Farber Cancer Institute suggests that blocking the PD-1 pathway could lead to a sustained clinical benefit in patients, potentially making continuous dosing of PD-1 or PD-L1 inhibitors

Read the full 318 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers